ONL Therapeutics: Leading The Charge In Medical Innovation!
Our mission is to develop innovative therapeutics to protect. Nov 1, 2023 · onl’s lead candidate, onl 1204, is currently in clinical trials for retinal detachment, open angle glaucoma and geographic atrophy. Onl 1204 is a small amino acid peptide that is. Ann arbor, mich. , sept. Nov 5, 2024 · onl therapeutics inc.
The ann arbor biotechnology startup netted the largest vc deal in the state in the third quarter,. Ann arbor, mich. , sept.